Tempus provides integrated solutions to help meet your needs from early discovery through commercialization.CONTACT US
Use our genomic platform to prospectively sequence through clinical trials and retrospectively support research priorities.
Integrate CDx claims into Tempus assays through a validated and established sequencing platform to pursue companion diagnostic biomarkers.
Utilize NGS and EMR integrations to identify patients that match your study's eligibility criteria, including targetable biomarkers from DNA and RNA.
Leverage real-world datasets of matched molecular and clinical data with digital whole slide pathology images to uncover new insights across the research and development spectrum.
Our AI algorithms run on top of common diagnostics modalities and give researchers new AI-driven insights to support clinicians’ management of their individual patients and potential trial eligibility.
Leverage our robust biobank of patient-derived tumor organoids to accelerate drug discovery.
Leverage our end to end solutions to design and execute Tempus-sponsored clinical trials for therapeutics, devices, and diagnostics from study concept to registrational filing.
of the top 20 pharma oncology companies partner with Tempus
de-identified research records to power scientific discovery to improve patient outcomes
records with matched clinical data linked with genomic information to understand driver mutations and outcomes associations
(approximately) records with full transcriptomic data for interrogating tumor biology and mechanisms of action
NGS tests to support clinical trial and research sequencing
oncologists rely on Tempus as their precision medicine partner
days on average to activate a new site (between April 2020–August 2021)
provider networks and research institutions in the TIME Trial® Program
patients were identified for potential enrollment into clinical trials in our network
Thanks to Tempus, we are able to identify patients that can be helped with our proprietary TMod™ platform. Without them, we wouldn’t be able to do this.
Tempus is a leader in the field of personalized medicine, and like Genmab, Tempus has a mission to improve the lives of cancer patients. We are looking forward to expanding our exciting partnership with them and to the possibility of discovering important new oncology targets and biomarkers.
Bayer’s strong focus in precision medicine combined with Tempus’ unique testing offering has culminated in this collaboration to bring genomic testing to cancer patients.
Our partnership with Tempus will enable us to collect important retrospective information about the patients enrolled in the dose escalation part of our clinical trial that we can potentially use to inform enrollment in the expansion stage of our study.
Kronos Bio and Tempus announced a continuation of their strategic partnership to give Kronos access to Tempus’ real-world genomic and transcriptomic data and data analytics tools.Read Article
FORTUNE has named Tempus to its 7th Change the World list, recognizing Tempus’ TIME Trial® Program for helping to bring trials to patients faster and closer to home.Read Article
Learn how Leap Therapeutics enhanced their understanding of a key biomarker for their clinical program in just a few months with Tempus Explore.Watch Webinar
Get customized solutions for your needs.
Thank you for contacting Tempus. We will respond shortly.